News stories about BIO-TECHNE (NASDAQ:TECH) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BIO-TECHNE earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.8757495518908 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
TECH stock traded up $1.46 during midday trading on Thursday, reaching $164.06. The stock had a trading volume of 117,700 shares, compared to its average volume of 177,524. The company has a quick ratio of 4.30, a current ratio of 5.55 and a debt-to-equity ratio of 0.37. The firm has a market cap of $6.05 billion, a price-to-earnings ratio of 47.97, a PEG ratio of 2.65 and a beta of 0.71. BIO-TECHNE has a twelve month low of $109.12 and a twelve month high of $164.24.
BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings data on Wednesday, May 2nd. The biotechnology company reported $1.21 EPS for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.07. BIO-TECHNE had a return on equity of 14.75% and a net margin of 18.29%. The firm had revenue of $164.00 million during the quarter, compared to analyst estimates of $163.43 million. During the same period last year, the company earned $0.97 earnings per share. The company’s revenue was up 13.9% on a year-over-year basis. sell-side analysts predict that BIO-TECHNE will post 4.05 earnings per share for the current fiscal year.
TECH has been the subject of a number of analyst reports. ValuEngine raised BIO-TECHNE from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub upgraded BIO-TECHNE from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 16th. Deutsche Bank set a $163.00 target price on BIO-TECHNE and gave the company a “buy” rating in a research note on Thursday, March 1st. Leerink Swann set a $160.00 target price on BIO-TECHNE and gave the company a “buy” rating in a research note on Thursday, May 3rd. Finally, Zacks Investment Research lowered BIO-TECHNE from a “buy” rating to a “hold” rating in a research note on Thursday, May 3rd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. BIO-TECHNE presently has a consensus rating of “Buy” and a consensus target price of $150.83.
In related news, CEO Charles R. Kummeth sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, June 7th. The stock was sold at an average price of $160.00, for a total transaction of $1,280,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.40% of the stock is owned by insiders.
BIO-TECHNE Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.